SYRE logo

Spyre Therapeutics (SYRE)

Profile

Full Name

Spyre Therapeutics, Inc.

Ticker Symbol

SYRE

Exchange

NASDAQ

Sector

Healthcare

Industry

Biotechnology

Country

United States

IPO

April 7, 2016

Indexes

Not included

Website

http://www.spyre.com

Employees

65

Key Details

Price

$12.22(+2.43%)

Market cap

$736.34M(Small cap)

Last Dividend

-

TTM Dividend yield

-

Annual revenue

-

Annual EPS

-$3.18(+76.89% YoY)

PE ratio

-

Next earnings date

May 9, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$12.22
SYRE price is $12.22

30-Day Relative Volume

0.75
SYRE 30-day relative volume is 0.75

Price Performance

Price Most recent change

+2.43%
SYRE price was up +2.43% on Apr 11, 2025

Price YTD change

-47.51%
SYRE price is down -47.51% since January 1st

Price 1-year change

-68.33%
SYRE price is down -68.33% year-on-year

Price 3-year change

-79.88%
SYRE price is down -79.88% over the past 3 years

Price Range

Price All-time high

$318.75
SYRE price is currently -96.17% below its historical high of $318.75

Price 3-year low

$2.65
SYRE price is currently +361.13% above its 3-year low

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Market cap

$736.34M
SYRE market capitalization is $736.34 million

Market cap 3-year change

+513.15%
SYRE market capitalization is up +513.15% over the past 3 years

Market cap All-time high

$2.11B
SYRE market capitalization is currently -65.17% below its historical high of $2.11 billion

Market cap sector rank

74.03%
SYRE market capitalization is higher than 74.03% of companies in Healthcare sector

Shares Outstanding

Shares Outstanding 1-Year Change

+64.5%
SYRE shares outstanding is up +64.5% year-on-year

Shares Outstanding 3-Year Change

+2948.21%
SYRE shares outstanding is up +2948.21% over the past 3 years

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Beta

1.70
SYRE beta is 1.70

200-day SMA

$25.48
SYRE price is currently -52.04% below its 200-day simple moving average

50-day SMA

$18.89
SYRE price is currently -35.32% below its 50-day simple moving average

RSI

31.50
SYRE 14-day relative strength index is 31.50

Volume

0.75
SYRE 30-day relative volume is 0.75

ATR

$1.47
SYRE average true range is $1.47

10-day Historical Volatility

118.52%
SYRE 10-day historical volatility is 118.52%

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Revenue

-
SYRE annual revenue value is unknown

Revenue Analysts estimate

-
SYRE annual revenue consensus analysts' forecast is unknown

Revenue 1-year change

-
SYRE annual revenue 1-year change is unknown

Revenue Sector rank

-
SYRE annual revenue is unknown

EPS

EPS

-$3.18
SYRE annual earnings per share is -$3.18

EPS Analysts estimate

-$3.46
SYRE annual earnings per share is currently -8.16% lower than the consensus analysts' forecast

EPS 1-year change

+76.89%
SYRE annual earnings per share is up +76.89% year-on-year

EPS Sector rank

27.99%
SYRE annual earnings per share is higher than 27.99% of companies in Healthcare sector

Profit

Gross profit

-
SYRE annual gross profit value is unknown

Gross margin

-
SYRE annual gross profit margin value is unknown

Operating profit

-$208.57M
SYRE annual operating income is -$208.57 million

Operating margin

-
SYRE annual operating profit margin value is unknown

Net income

-$208.02M
SYRE annual net profit is -$208.02 million

Net margin

-
SYRE annual net profit margin value is unknown

Expenses

Total expenses

$208.57M
SYRE annual total expenses is $208.57 million

Operating expenses

$208.57M
SYRE annual total operating expenses is $208.57 million

Cost of goods sold

-
SYRE annual cost of goods sold value is unknown

Selling, general & administrative expenses

$45.78M
SYRE annual SGA is $45.78 million

Depreciation and amortization

$0.00
SYRE annual depreciation & amortization is $0.00

Interest expense

-
SYRE annual interest expense value is unknown

Income tax

$51.00K
SYRE annual income tax is $51.00 thousand

EBIT & EBITDA

EBIT

-$208.57M
SYRE annual earnings before interest & taxes is -$208.57 million

EBITDA

-$208.57M
SYRE annual EBITDA is -$208.57 million

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Total assets

$608.48M
SYRE annual total assets is $608.48 million

Non current assets

$10.00K
SYRE annual long term assets is $10.00 thousand

Current assets

$608.47M
SYRE annual total current assets is $608.47 million

Cash and cash equivalents

$89.42M
SYRE annual cash & cash equivalents is $89.42 million

Accounts receivable

-
SYRE annual accounts receivable value is unknown

Inventory

-
SYRE annual inventory value is unknown

Liabilities

Total liabilities

$90.68M
SYRE annual total liabilities is $90.68 million

Long term liabilities

$36.62M
SYRE annual total long term liabilities is $36.62 million

Current liabilities

$54.06M
SYRE annual total current liabilities is $54.06 million

Accounts payable

$666.00K
SYRE annual accounts payable is $666.00 thousand

Debt

Total debt

$0.00
SYRE annual total debt is $0.00

Total debt 1-year change

0%
SYRE {parameterFullLabel} has remained unchanged year-on-year

Long term debt

-
SYRE annual long term debt value is unknown

Short term debt

-
SYRE annual short term debt value is unknown

Equity & Capital

Shareholders equity

$517.80M
SYRE annual stockholders equity is $517.80 million

Book value

$361.98M
SYRE annual book value is $361.98 million

Retained earnings

-$972.43M
SYRE annual retained earnings is -$972.43 million

Working capital

$554.41M
SYRE annual working capital is $554.41 million

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Cash from operations

-$157.41M
SYRE annual cash flow from operations is -$157.41 million

Cash from operations 1-year change

-57.55%
SYRE annual cash flow from operations is down -57.55% year-on-year

Cash from investing

-$353.29M
SYRE annual cash flow from investing activities is -$353.29 million

Cash from investing 1-year change

-225.93%
SYRE annual cash flow from investing activities is down -225.93% year-on-year

Cash from financing

$410.91M
SYRE annual cash flow from financing activities is $410.91 million

Cash from financing 1-year change

+13.8%
SYRE annual cash flow from financing activities is up +13.8% year-on-year

CAPEX

CAPEX

-
SYRE annual capital expenditures value is unknown

CAPEX 1-year change

-
SYRE annual capital expenditures 1-year change is unknown

Free Cash Flow

Free cash flow

-$157.41M
SYRE annual free cash flow is -$157.41 million

Free cash flow 1-year change

-57.55%
SYRE annual free cash flow is down -57.55% year-on-year

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

Gross margin

-
SYRE annual gross profit margin value is unknown

Operating margin

-
SYRE annual operating profit margin value is unknown

Net margin

-
SYRE annual net profit margin value is unknown

ROA & ROE

ROA

-34.19%
SYRE annual return on assets is -34.19%

ROE

-40.17%
SYRE annual return on equity is -40.17%

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE ratio

-
SYRE price to earnings ratio value is unknown

PE ratio Sector rank

-
SYRE price to earnings ratio is unknown

PB Ratio

PB ratio

2.03
SYRE price to book ratio is 2.03

PB ratio Sector rank

63.4%
SYRE price to book ratio is higher than 63.4% of companies in Healthcare sector

PS Ratio

PS ratio

-
SYRE price to sales ratio value is unknown

PS ratio Sector rank

-
SYRE price to sales ratio is unknown

Enterprise value

Enterprise value

$646.92M
SYRE enterprise value is $646.92 million

Enterprise value Sector rank

72.14%
SYRE enterprise value is higher than 72.14% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-3.10
SYRE EV/EBITDA is -3.10

EV/EBITDA Sector rank

25%
SYRE EV/EBITDA is higher than 25% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Current ratio

11.26
SYRE annual current ratio is 11.26

Quick ratio

-
SYRE annual quick ratio value is unknown

Leverage

Debt to equity

0.00
SYRE annual debt to equity ratio is 0.00

Interest coverage ratio

-
SYRE annual interest coverage ratio value is unknown

Risk & Stability

Piotroski F-Score

-
SYRE piotroski f-score value is unknown

Altman Z-Score

-
SYRE altman z-score value is unknown

Analyst ratings

Recent major analysts updates

Apr 8, 25 Leerink Partners
Outperform
Dec 11, 24 Jones Trading
Hold
Nov 13, 24 Baird
Outperform
Oct 25, 24 Guggenheim
Buy
Sep 4, 24 Wedbush
Outperform
Jul 16, 24 Evercore ISI Group
Outperform
May 13, 24 Wells Fargo
Overweight
May 10, 24 BTIG
Buy
May 2, 24 Baird
Outperform
Mar 26, 24 Stifel
Buy

Institutional Ownership

Similar stocks

ZYME logo
Zymeworks (ZYME)
AVDL logo
Avadel Pharmaceuticals (AVDL)
MYGN logo
Myriad Genetics (MYGN)
NUTX logo
Nutex Health (NUTX)
AMN logo
AMN Healthcare Services (AMN)
DAWN logo
Day One Biopharmaceuticals (DAWN)
AVXL logo
Anavex Life Sciences (AVXL)
HCSG logo
Healthcare Services (HCSG)
CVAC logo
CureVac NV (CVAC)
  • What is the ticker symbol for Spyre Therapeutics?
  • Does Spyre Therapeutics pay dividends?
  • What sector is Spyre Therapeutics in?
  • What industry is Spyre Therapeutics in?
  • What country is Spyre Therapeutics based in?
  • When did Spyre Therapeutics go public?
  • Is Spyre Therapeutics in the S&P 500?
  • Is Spyre Therapeutics in the NASDAQ 100?
  • Is Spyre Therapeutics in the Dow Jones?
  • When was Spyre Therapeutics's last earnings report?
  • When does Spyre Therapeutics report earnings?
  • Should I buy Spyre Therapeutics stock now?

What is the ticker symbol for Spyre Therapeutics?

The ticker symbol for Spyre Therapeutics is NASDAQ:SYRE

Does Spyre Therapeutics pay dividends?

No, Spyre Therapeutics does not pay dividends

What sector is Spyre Therapeutics in?

Spyre Therapeutics is in the Healthcare sector

What industry is Spyre Therapeutics in?

Spyre Therapeutics is in the Biotechnology industry

What country is Spyre Therapeutics based in?

Spyre Therapeutics is headquartered in United States

When did Spyre Therapeutics go public?

Spyre Therapeutics's initial public offering (IPO) was on April 7, 2016

Is Spyre Therapeutics in the S&P 500?

No, Spyre Therapeutics is not included in the S&P 500 index

Is Spyre Therapeutics in the NASDAQ 100?

No, Spyre Therapeutics is not included in the NASDAQ 100 index

Is Spyre Therapeutics in the Dow Jones?

No, Spyre Therapeutics is not included in the Dow Jones index

When was Spyre Therapeutics's last earnings report?

Spyre Therapeutics's most recent earnings report was on Feb 27, 2025

When does Spyre Therapeutics report earnings?

The next expected earnings date for Spyre Therapeutics is May 9, 2025

Should I buy Spyre Therapeutics stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page